

AMENDMENTS TO THE CLAIMS

1-21. (Cancelled)

22. (Currently Amended) A method for the production of a diabody-type bispecific antibody, comprising assembling the single-chain polypeptides produced by the method of Claim 28 to form a diabody-type bispecific antibody

culturing a host cell transformed with a nucleic acid encoding a first polypeptide of claim 28,

culturing a host cell transformed with a nucleic acid encoding a second polypeptide of claim 28,

expressing the nucleic acids,

collecting the expressed first and second polypeptides,

purifying the first and second polypeptides, and

assembling the first and second polypeptides to form the diabody-type bispecific antibody of claim 28, and

separating and collecting the diabody-type antibody.

23. (Cancelled)

24. (Previously Presented) A pharmaceutical preparation comprising the diabody-type bispecific antibody according to claim 28.

25. (Currently Amended) The pharmaceutical preparation according to Claim 24 for use in increasing the production of cytokines by [[the]] cells expressing CD3, and having phagocytosis or cytotoxic activity.

26. (Cancelled)

27. (Currently Amended) A method for increasing the production of cytokines by [[the]] cells expressing CD3, and having phagocytosis or cytotoxic activity, comprising adding the diabody-type bispecific antibody according to Claim 28 to a culture system containing the cells expressing CD3, and having phagocytosis or cytotoxic activity, and tumor cells expressing the human EGF ~~receptors~~ receptor, HER-1/ErbB1.

28. (Previously Presented) A humanized diabody-type bispecific antibody selected from the group of (A)-(D) consisting of:

(A) a first single-chain polypeptide comprising

a heavy chain comprising a variable region comprising the amino acid sequence according to SEQ ID NO:43, and a light chain comprising a variable region comprising the amino acid sequence according to SEQ ID NO:46, and

a second single-chain polypeptide comprising

a light chain comprising a variable region comprising the amino acid sequence according to SEQ ID NO:44, and a heavy chain comprising a variable region comprising the amino acid sequence according to SEQ ID NO:45,

(B) a first single-chain polypeptide comprising

a heavy chain comprising a variable region comprising the amino acid sequence according to SEQ ID NO:43 and a light chain comprising a variable region comprising the amino acid sequence according to SEQ ID NO:46, and

a second single-chain polypeptide comprising a light chain comprising a variable region comprising the amino acid sequence according to SEQ ID NO:44 and a heavy chain comprising a variable region comprising the amino acid sequence according to SEQ ID NO:45,

wherein Met at position 48 and Ala at position 93 of the heavy chain sequence according to SEQ ID NO:45 are replaced by Ile and Thr, respectively

(C) a first single-chain polypeptide comprising

a heavy chain comprising a variable region comprising the amino acid sequence according to SEQ ID NO:43 and a light chain comprising a variable region comprising the amino acid sequence according to SEQ ID NO:46, and

a second single-chain polypeptide comprising

a light chain comprising a variable region comprising the amino acid sequence according to SEQ ID NO:44 and a heavy chain comprising a variable region comprising the amino acid sequence according to SEQ ID NO:45,

wherein Arg at position 66, Met at position 69, Arg at position 71 and Thr at position 73 of the heavy chain sequence according to SEQ ID NO:45 are replaced by Lys, Leu, Val and Arg, respectively, and

(D) a first single-chain polypeptide comprising

a heavy chain comprising a variable region comprising the amino acid sequence

according to SEQ ID NO:43 and a light chain comprising a variable region comprising the amino acid sequence according to SEQ ID NO:46, and

a second single-chain polypeptide comprising

a light chain comprising a variable region comprising the amino acid sequence according to SEQ ID NO:44 and a heavy chain comprising a variable region comprising the amino acid sequence according to SEQ ID NO:45,

wherein Met at position 48, Arg at position 66, Met at position 69, Arg at position 71, Thr at position 73 and Ala at position 93 of the heavy chain sequence according to SEQ ID NO:45 are replaced by Ile, Lys, Leu, Val, Arg and Thr, respectively.

29. (Previously Presented) The humanized diabody-type bispecific antibody according to claim 28 which is (A).

30. (Previously Presented) The humanized diabody-type bispecific antibody according to claim 28 which is (B).

31. (Previously Presented) The humanized diabody-type bispecific antibody according to claim 28 which is (C).

32. (Previously Presented) The humanized diabody-type bispecific antibody according to claim 28 which is (D).